During the last three months, 18 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 8 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 5 | 7 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $302.44, a high estimate of $364.00, and a low estimate of $240.00. Experiencing a 5.59% decline, the current average is now lower than the previous average price target of $320.36.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how...
Login or create a forever free account to read this news
Sign up/Log in